atovaquone has been researched along with metronidazole in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 6 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Bathurst, I; Burrows, JN; Charman, SA; Cross, RM; Flanigan, DL; Fronczek, FR; Guida, WC; Kyle, DE; LaCrue, AN; Maignan, JR; Manetsch, R; Monastyrskyi, A; Mutka, TS; Sáenz, FE; Shackleford, DM; White, KL; Wojtas, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Azas, N; Basmaciyan, L; Belle Mbou, V; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, É; Casanova, M; Castera-Ducros, C; Cohen, A; Courtioux, B; Fairlamb, AH; Fersing, C; Hutter, S; Laget, M; Milne, R; Pedron, J; Piednoel, M; Primas, N; Rathelot, P; Since, M; Sournia-Saquet, A; Valentin, A; Vanelle, P; Verhaeghe, P; Wyllie, S | 1 |
Abdel-Aziz, A; Azab, MS; El-Tantawy, NL; Elmehankar, MS; Hegazy, MM | 1 |
1 review(s) available for atovaquone and metronidazole
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 other study(ies) available for atovaquone and metronidazole
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
Topics: Animals; Antimalarials; Humans; Inhibitory Concentration 50; Malaria; Mice; Microsomes, Liver; Parasitemia; Plasmodium; Plasmodium berghei; Quinolones; Structure-Activity Relationship | 2014 |
Nongenotoxic 3-Nitroimidazo[1,2-
Topics: | 2019 |
Sex dichotomy in the course of experimental latent toxoplasmosis.
Topics: Animals; Antibodies, Protozoan; Atovaquone; Brain; Chronic Disease; Coccidiostats; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Estradiol; Female; Immunoglobulin G; Interleukin-12; Male; Metronidazole; Mice; Morbidity; Sex Factors; Spiramycin; Testosterone Propionate; Toxoplasma; Toxoplasmosis, Animal | 2019 |